Audience -All Patients & Families-Adults & Aging-Chapters-Donors & Supporters-Healthcare Providers-Kids & Young Adults-Men-Payers-Spanish Speaking Individuals-Undiagnosed-Women & Girls Type of Bleeding Disorder -All Bleeding Disorders-Hemophilia-Inhibitors-Rare Bleeding Disorders-Von Willebrand Disease Topic -Advocacy-Awareness-Blood & Product Safety-Bone & Joint Health-Community-COVID-19-Digital Health-Diversity, Equity & Inclusion-Fitness & Nutrition-Future Therapies-Health Equity-Healthcare Insurance-HIV & Hepatitis C-Mental Health-Pain Management-Sexual & Reproductive Health-Research-Treatment & Care 01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022 18 May Implementation Science May 18, 2022 - May 18, 2022 16 Mar Breakthrough Bleeding Episodes in Pediatric Severe Hemophilia a Patients with and without Inhibitors Receiving Emicizumab Prophylaxis: a Single-center Retrospective Review Mar 16, 2022 09 Jun Danger Signals and Inhibitor Development Jun 9, 2021 - Jun 9, 2021 29 May Town Hall Webinar - Inhibitors: Coping During COVID-19 May 29, 2020
01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022
16 Mar Breakthrough Bleeding Episodes in Pediatric Severe Hemophilia a Patients with and without Inhibitors Receiving Emicizumab Prophylaxis: a Single-center Retrospective Review Mar 16, 2022
